Crossmark

Development of an iPSC-derived tissue-resident macrophage-based platform for the in vitro immunocompatibility assessment of human tissue engineered matrices

Crossref DOI link: https://doi.org/10.1038/s41598-024-62745-1

Published Online: 2024-05-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Poulis, Nikolaos

Martin, Marcy

Hoerstrup, Simon P.

Emmert, Maximilian Y.

Fioretta, Emanuela S.
Funding

Funding for this research was provided by:

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PZ00P3_180138)

European Research Council (852814 (TAVI4Life))
License Information

Text and Data Mining valid from 2024-05-28

Version of Record valid from 2024-05-28
More Information

Article History

Received: 5 February 2024

Accepted: 21 May 2024

First Online: 28 May 2024

Competing interests

: S.P.H. is a shareholder at Xeltis BV and LifeMatrix Technologies AG. M.Y.E. is a shareholder at LifeMatrix Technologies AG. All other authors declare no competing interests.

Document is current

Any future updates will be listed below